Oseltamivir-resistant Influenza A and B Viruses Pre- and Postantiviral Therapy in Children and Young Adults with Cancer

Overview

Journal Pediatr Infect Dis J

Specialty Pediatrics

Date 2010 Nov 5

PMID 21048522

Citations 31

Authors

Silvana Carr

Natalia A Ilyushina

John Franks

Elisabeth E Adderson

Miguela Caniza

Elena A Govorkova

Robert G Webster

Affiliations

Soon will be listed here.

Abstract

Background: Immunocompromised patients are highly susceptible to influenza infection and can have prolonged viral shedding, which is a risk factor for the development of antiviral resistance.

Methods: We investigated the emergence of oseltamivir-resistant influenza variants in children and young adults with cancer during the 2002-2008 influenza seasons. The demographic and clinical features of influenza infections in 12 patients who had viral isolates obtained before and after oseltamivir therapy was initiated were studied. Antiviral susceptibilities were determined by the fluorescence-based neuraminidase (NA) enzyme inhibition assay and by sequencing genes encoding NA and matrix M2 proteins.

Results: The mean age of patients was 10.5 (range, 1.1-23.0) years. Ten patients had hematologic malignancies, 4 were recipients of hematopoietic stem cell transplants, and all patients were receiving immunosuppressive therapy. Eleven patients had prolonged respiratory symptoms and 8 had prolonged viral shedding. Serial viral isolates were available for 8 of 12 patients. Oseltamivir-resistant influenza viruses were isolated from 4 children (3 influenza A [H3N2] and 1 influenza B virus): before the initiation of antiviral therapy in 2 patients and during therapy in the other 2 patients. Three resistant influenza A (H3N2) viruses shared a common E119V NA mutation. One patient was infected with oseltamivir-resistant influenza B virus (IC50, 731.86 ± 155.12 nM) that harbored a N294S NA mutation, the first report of this mutation in influenza B viruses.

Conclusions: Oseltamivir-resistant influenza viruses can exist before or rapidly emerge during antiviral therapy in immunocompromised individuals, and this has important implications for therapy and infection control.

Citing Articles

Approach to hematopoietic cell transplant candidates with respiratory viral detection.

Kim S, Waghmare A, Hijano D Front Pediatr. 2024; 11:1339239.

PMID: 38304442 PMC: 10830789. DOI: 10.3389/fped.2023.1339239.

Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with antiviral efficacy against both oseltamivir sensitive and -resistant influenza A viruses.

Caceres C, Hu Y, Cardenas-Garcia S, Wu X, Tan H, Carnaccini S Emerg Microbes Infect. 2021; 10(1):1832-1848.

PMID: 34427541 PMC: 8451667. DOI: 10.1080/22221751.2021.1972769.

Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance.

Bai Y, Jones J, Wong S, Zanin M Viruses. 2021; 13(4).

PMID: 33917376 PMC: 8067422. DOI: 10.3390/v13040624.

Influenza B viruses from different genetic backgrounds are variably impaired by neuraminidase inhibitor resistance-associated substitutions.

Pascua P, Marathe B, Bisen S, Webby R, Govorkova E Antiviral Res. 2019; 173:104669.

PMID: 31790712 PMC: 11409462. DOI: 10.1016/j.antiviral.2019.104669.

Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model.

Pascua P, Marathe B, Vogel P, Webby R, Govorkova E J Antimicrob Chemother. 2019; 74(5):1333-1341.

PMID: 30715325 PMC: 6477984. DOI: 10.1093/jac/dky560.

References

Gubareva L, Matrosovich M, Brenner M, Bethell R, Webster R . Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 1998; 178(5):1257-62. DOI: 10.1086/314440. View

Zambon M, Hayden F . Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. 2001; 49(3):147-56. DOI: 10.1016/s0166-3542(01)00124-3. View

Moscona A . Neuraminidase inhibitors for influenza. N Engl J Med. 2005; 353(13):1363-73. DOI: 10.1056/NEJMra050740. View

Mungall B, Xu X, Klimov A . Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus Res. 2004; 103(1-2):195-7. DOI: 10.1016/j.virusres.2004.02.033. View

McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M . Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother. 2003; 47(7):2264-72. PMC: 161875. DOI: 10.1128/AAC.47.7.2264-2272.2003. View

Six H, Webster R, Kendal A, Glezen W, Griffis C, Couch R . Antigenic analysis of H1N1 viruses isolated in the Houston metropolitan area during four successive seasons. Infect Immun. 1983; 42(2):453-8. PMC: 264451. DOI: 10.1128/iai.42.2.453-458.1983. View

Memoli M, Jagger B, Dugan V, Qi L, Jackson J, Taubenberger J . Recent human influenza A/H3N2 virus evolution driven by novel selection factors in addition to antigenic drift. J Infect Dis. 2009; 200(8):1232-41. PMC: 2778484. DOI: 10.1086/605893. View

Johny A, Clark A, Price N, Carrington D, Oakhill A, Marks D . The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone Marrow Transplant. 2002; 29(2):113-5. DOI: 10.1038/sj.bmt.1703343. View

Hoffmann E, Stech J, Guan Y, Webster R, Perez D . Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol. 2002; 146(12):2275-89. DOI: 10.1007/s007050170002. View

10.

Gubareva L . Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 2004; 103(1-2):199-203. DOI: 10.1016/j.virusres.2004.02.034. View

11.

Treanor J, Hayden F, Vrooman P, Barbarash R, Bettis R, Riff D . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000; 283(8):1016-24. DOI: 10.1001/jama.283.8.1016. View

12.

Wang C, Takeuchi K, Pinto L, Lamb R . Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol. 1993; 67(9):5585-94. PMC: 237962. DOI: 10.1128/JVI.67.9.5585-5594.1993. View

13.

Le Q, Kiso M, Someya K, Sakai Y, Nguyen T, Nguyen K . Avian flu: isolation of drug-resistant H5N1 virus. Nature. 2005; 437(7062):1108. DOI: 10.1038/4371108a. View

14.

Aoki F, Boivin G, Roberts N . Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther. 2007; 12(4 Pt B):603-16. View

15.

Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, Kimura K . Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis. 2006; 44(2):197-202. DOI: 10.1086/509925. View

16.

Monto A, McKimm-Breschkin J, Macken C, Hampson A, Hay A, Klimov A . Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother. 2006; 50(7):2395-402. PMC: 1489772. DOI: 10.1128/AAC.01339-05. View

17.

Ison M, Mills J, Openshaw P, Zambon M, Osterhaus A, Hayden F . Current research on respiratory viral infections: Fourth International Symposium. Antiviral Res. 2002; 55(2):227-78. PMC: 7172682. DOI: 10.1016/s0166-3542(02)00055-4. View

18.

Roberts N . Treatment of influenza with neuraminidase inhibitors: virological implications. Philos Trans R Soc Lond B Biol Sci. 2002; 356(1416):1895-7. PMC: 1088566. DOI: 10.1098/rstb.2001.1002. View

19.

Hurt A, Barr I, Durrant C, Shaw R, Sjogren H, Hampson A . Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia. Commun Dis Intell Q Rep. 2004; 27(4):542-7. View

20.

Abed Y, Baz M, Boivin G . Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther. 2007; 11(8):971-6. View